Skip to main content
. 2014 Oct 3;9(10):e108107. doi: 10.1371/journal.pone.0108107

Table 1. Characteristics of those with isolated (i-CNS) or combined (c-CNS) CNS relapses compared with those with an isolated bone marrow relapse (i-BM).

c-CNS i-CNS i-BM
N 43 80 207
Age at relapse in years
median (25th−75th) 8·7 (6·8–13·7) 8·4 (6·1–11·5) 9·75 (7–13·4)
Range 2·5–18·8 2·0–17·9 1·1–18·8
Gender
Male:Female 27∶16 61∶19 104∶103
Ratio 1·7∶1 3·2∶1 1∶1
Time to Relapse in months
median (25th−75th) 37 (23–47) 27 (21–34·3) 44 (33–61)
Range 6–92 5–90 5–155
Late 20 (47%) 12 (15%) 142 (69%)
Early 16 (37%) 55 (69%) 48 (23%)
Very Early 7 (16%) 13 (16%) 17 (8%)
Risk category (%)
Standard - 12 (15%) -
Intermediate 20 (47%) 68 (85%) 135 (65%)
High 23 (53%) - 72 (35%)
Immunophenotype
B:T 36∶7 61∶19 189∶18
Ratio 5∶1 3∶1 11∶1
CSF blast count
median (range) 97 (14–188) 97 (27–392) NA
Bone Marrow Blast %
median (range) 83·5 (48·5–95) NA 90 (78–95)
Cytogenetics (%)
progenitor B
Good 15 (35) 28 (35) 77 (37)
Intermediate 11 (25) 18 (23) 63 (30)
Poor 5 (12) 6 (8) 34 (16)
Unknown 5 (12) 9 (11) 15 (7)
T-cell 7 (16) 19 (24) 18 (9)

Relapses within 18 months of first diagnosis were termed as Very Early; after 18 months but within 6 months of stopping therapy as Early and after 6 months of stopping therapy as Late. B = progenitor B cell; T = T-cell; CSF = cerebrospinal fluid. CSF blast count is presented as cells/µl of CSF. Risk stratification and cytogenetic classification have previously been described.